Novartis AG v Pharmacor Pty Limited

Link copied
Case Copied 23 min read

FEDERAL COURT OF AUSTRALIA

Novartis AG v Pharmacor Pty Limited [2025] FCAFC 33  

Appeal from: Novartis AG v Pharmacor Pty Limited (No 3) [2024] FCA 1307
File number(s): NSD 1811 of 2024
Judgment of: BURLEY, ROFE AND DOWNES JJ
Date of judgment: 19 March 2025
Date of publication of reasons: 24 March 2025
Catchwords:

PATENTS – infringement – standard patent for a pharmaceutical composition containing certain active pharmaceutical ingredients – claim construction – whether primary judge erred in construction of claim as not including a pharmaceutical composition where the active pharmaceutical ingredient is in the form of a complex in which the ions are associated by non-covalent bonds – no error shown

PATENTS – extension of patent term – appeal against primary judge’s finding that the extension of term was not validly granted – s 70 Patents Act 1990 (Cth) – no error shown

Legislation: Patents Act 1990 (Cth) ss 40(3), 70, 70(2)(a)
Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 54
Date of hearing: 18-19 March 2025
Counsel for the Appellants: Mr T Cordiner KC and Mr B Mee
Solicitor for the Appellants: Clayton Utz
Counsel for the Respondent: Mr J Cooke SC and Mr D Larish
Solicitor for the Respondent: Ashurst

ORDERS

NSD 1811 of 2024
BETWEEN:

NOVARTIS AG

First Appellant

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED (ACN 004 244 162)

Second Appellant

AND:

PHARMACOR PTY LIMITED (ACN 121 020 835)

Respondent

AND BETWEEN:

PHARMACOR PTY LIMITED (ACN 121 020 835)

Cross-Appellant

AND:

NOVARTIS AG (and another named in the Schedule)

First Cross-Respondent

ORDER MADE BY:

BURLEY, ROFE AND DOWNES JJ

DATE OF ORDER:

19 MARCH 2025

THE COURT ORDERS THAT:

1.The appeal be dismissed.

2.The cross-appeal be dismissed.

3.The interlocutory application filed by the appellants on 16 December 2024 be dismissed with costs.

4.The appellants pay the respondent’s costs of the appeal and the cross-appeal.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

INTRODUCTION

[1]

CONSTRUCTION

[12]

Claim 1

[12]

The primary judge’s reasoning in relation to construction

[13]

The construction appeal

[31]

INFRINGEMENT

[53]

PATENT TERM EXTENSION

[54]

THE COURT:

INTRODUCTION

  1. This is an appeal from the decision of Novartis AG v Pharmacor Pty Limited (No 3) [2024] FCA 1307 (J).  The appeal was brought on for an expedited hearing for reasons which are explained below.

  2. The primary issue on the appeal concerned the construction of claim 1 of patent No. 2003206738 entitled “Pharmaceutical compositions comprising valsartan and NEP inhibitors”.

  3. The appellants, Novartis AG and Novartis Pharmaceuticals Australia Pty Ltd (together, Novartis) contended that the primary judge erred in his construction of the claim and in failing to find that the respondent, Pharmacor Pty Limited, had threatened to engage in acts of infringement of that claim by signalling its intention to supply in Australia pharmaceutical products entered on the Australian Register of Therapeutic Goods (ARTG) identified in the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2025] FCAFC 33
Decision Date

CaseChat Overview and Summary

In the matter of Novartis AG versus Pharmacor Pty Limited, the dispute centred around the validity of a patent granted to Novartis for a pharmaceutical composition. The primary dispute was whether Pharmacor had infringed the patent by manufacturing and selling a pharmaceutical composition that contained certain active pharmaceutical ingredients. The matter was heard in the Federal Court of Australia.

The legal issues that the court had to decide included whether the primary judge had erred in the construction of a claim of the patent. Specifically, it was questioned whether the claim included a pharmaceutical composition where the active pharmaceutical ingredient was in the form of a complex in which the ions were associated by non-covalent bonds. The court also had to determine if there was an error in the primary judge’s finding that the extension of the patent term was not validly granted under section 70 of the Patents Act 1990 (Cth).

The court found that no error had been demonstrated in the primary judge's construction of the patent claim. The court reasoned that the claim did not encompass a pharmaceutical composition where the active pharmaceutical ingredient was in the form of a complex in which the ions were associated by non-covalent bonds. Additionally, the court held that there was no error in the primary judge’s determination that the extension of the patent term was not validly granted, as required by section 70 of the Patents Act 1990 (Cth). Therefore, the appeal and the cross-appeal were dismissed. Furthermore, the interlocutory application filed by the appellants was dismissed with costs. The appellants were ordered to pay the respondent’s costs of the appeal and the cross-appeal.

Orders

Orders of the court

1. The appeal be dismissed.

2. The cross-appeal be dismissed.

3. The interlocutory application filed by the appellants on 16 December 2024 be dismissed with costs.

4. The appellants pay the respondent’s costs of the appeal and the cross-appeal.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established